Introduction Acute myeloid leukemia (AML) is a heterogeneous clonal disorder often associated with dismal overall survival. The clinical diversity of AML is reflected in the range of recurrent somatic mutations in several genes, many of which have a prognostic and therapeutic value. Targeted next-generation sequencing (NGS) of these genes has the potential for translation into clinical practice. In order to assess this potential, an inter-laboratory evaluation of a commercially available AML gene panel across three diagnostic centres in the UK and Ireland was performed. Methods DNA from six AML patient samples was distributed to each centre and processed using a standardised workflow, including a common sequencing platform, sequencing chips and bioinformatics pipeline. A duplicate sample in each centre was run to assess inter-and intralaboratory performance. Results An average sample read depth of 2725X (range 629-5600) was achieved using six samples per chip, with some variability observed in the depth of coverage generated for individual samples and between centres. A total of 16 somatic mutations were detected in the six AML samples, with a mean of 2.7 mutations per sample (range 1-4) representing nine genes on the panel. 15/16 mutations were identified by all three centres. Allelic frequencies of the mutations ranged from 5.6 to 53.3 % (median 44.4 %), with a high level of concordance of these frequencies between centres, for mutations detected. Conclusion In this inter-laboratory comparison, a high concordance, reproducibility and robustness was demonstrated using a commercially available NGS AML gene panel and platform.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterised by infiltration of the bone marrow, blood and other tissues by abnormal or poorly differentiated myeloid cells of the haematopoietic system. Diagnosis is based on bone marrow and peripheral blood morphology, immunophenotype and the presence of typical chromosomal alterations or recurrent mutations. Treatment for AML patients is primarily based on delivery of an intensive course of induction chemotherapy, such as cytarabine plus anthracycline, followed by post-remission consolidation chemotherapy. Up to 80 % of patients achieve complete remission, however a significant proportion will eventually relapse [1] . Allogeneic transplantation offers the potential of a curative therapy in eligible patients after careful assessment of co-existing morbidities based on donor availability and genetic profile. Recurrent genetic lesions such as Fms-related tyrosine kinase 3 (FLT3), CCAAT/ enhancer binding protein-a (CEBPA) and nucleophosmin (NPM1) are commonly used as prognostic markers in clinical practice, with markers associated with poor outcome, such as tumour protein 53 (TP53), additional sex combs like transcriptional regulator 1 (ASXL1) and runtrelated transcription factor 1 (RUNX1), likely to be recommended for stratification in forthcoming guidelines [2] . Next-generation sequencing (NGS) technologies allow massive parallel sequencing of multiple DNA regions of interest, including large or GC-rich genes, and offer the potential for increased throughput, sensitivity and quantification of variant allelic frequencies relative to standard Sanger sequencing. Recent application of genomic techniques such as whole genome sequencing have yielded a broad view of the mutational landscape of AML, and highlighted 25-30 recurrent somatic mutations that can be organised into functional categories. These genes encode for transcription factors and tumour suppressors, genes related to DNA methylation, haematopoietic cytokine signalling, chromatin modification, the cohesin complex and the spliceosome complex [3] . Further studies have described patterns of clonal and subclonal evolution, mutation clearance rates post-induction therapy and the monitoring of minimal residual disease [4] [5] [6] [7] . Together, these advances are helping unravel the potential for new personalised therapies and targeted treatments with specific agents used in combinations with standard chemotherapy to maintain remission or bridge to transplantation [2, 8] . The adoption of targeted gene panels comprising a refined set of diseaserelevant genes has shown promise for translation of NGS into clinical practice [9] [10] [11] . Here we present an interlaboratory evaluation of a commercially available AML gene panel across three clinical diagnostic centres in the UK and Ireland.
Material and Methods
To evaluate the AML NGS panel, DNA from six precharacterised AML patients (NPM1 and FLT3-ITD mutation status assessed by polymerase chain reaction [PCR] and capillary electrophoresis using alternative laboratory methods) was used for quality control (QC#1-6), distributed to each centre and processed using standardised workflows for the Ion Ampliseq TM AML Panel (Life Technologies/Thermo Fisher Scientific, Paisley, UK) before sequencing on an Ion Torrent Personalized Genome Machine (PGM TM ; Life Technologies/Thermo Fisher Scientific). A designated sample (QC#3, QC#5, and QC#6) was repeated in duplicate on separate runs in centres 1, 3 and 2, respectively, to assess inter-and intra-centre reproducibility. Amplicon libraries covering 19 commonly mutated genes implicated in AML and covering the entire coding region of DNA (cytosine-5-)-methyltransferase 3-a (DNMT3A), CEBPA, GATA binding protein 2 (GATA2), tet methylcytosine dioxygenase 2 (TET2), TP53 and mutational hot-spot regions of ASXL1, B-raf proto-oncogene, serine/threonine kinase (BRAF), Cbl proto-oncogene, E3 ubiquitin protein ligase (CBL), FLT3 (tyrosine kinase domain mutations), isocitrate dehydrogenase 1 (IDH1), isocitrate dehydrogenase 2 (IDH2), Janus kinase 2 (JAK2), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), Kirsten rat sarcoma viral oncogene homolog (KRAS), NPM1, neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), protein tyrosine phosphatase, non-receptor type 11 (PTPN11), RUNX1 and Wilms tumour 1 (WT1), were generated using 10 ng genomic DNA in each of four primer-pooled reactions generating 264 amplicons.
Amplified targets were combined from four pools to two, primer sequences were partly digested and barcoded adapters were ligated for sample identification. The resulting product was purified using Agencourt Ò AMPure Coverage in highly sampled locations was capped at 2000X to reduce computational time. Calling of somatic mutations was achieved using an algorithm that excluded synonymous mutations, variants located within intronic or untranslated regions, and variants present at a frequency of \5 %. Insertions/deletions called using Ion Reporter TM were confirmed by reviewing data with the Broad Institute's Integrative Genomics Viewer (IGV) [12] . In addition, AcroMetrix controls (Life Technologies/Thermo Fisher Scientific), a highly multiplexed QC used to assess the performance of NGS assays, was employed in one centre to determine variant detection at low variant allele frequencies (VAFs). To maximise confidence in variant calling, a minimum target depth of coverage for variant calls was set at 500X based on these data, with potential somatic variants reviewed and screened using relevant public databases, such as dbSNP, ClinVar, COSMIC, and PubMed. No homozygous mutations of somatic relevance were detected using the aforementioned public databases.
Results

Platform Performance
Performance of the Ion PGM TM platform and workflow at each centre was assessed using the QC data generated for each sample. Variables assessed were the number of reads generated, the number and AQ20 (1 % error rate) quality score of bases, the average depth of coverage across the bases and the average read length generated. A mean read count of 602,354 reads per sample (range 150,312-1,212,941) was generated. Mean read length at AQ20 was consistent at 123 bp (CV 3.3 %) for all samples analysed. An average sample read depth of 2725X (range 629-5600) was achieved using six samples on a 318 TM v2 chip, with significant variability observed in the depth of coverage generated for individual QC samples and between centres (electronic supplementary Table 1 ). AcroMetrix controls showed detection of applicable variants present in IDH1/2, KIT, NPM1, PTPN11, FLT3, TP53, KRAS and NRAS at VAFs of between 5 and 10 % (25 % for NPM1) at 500X as expected.
Somatic Mutation Detection
Unfiltered data files from each centre were downloaded from Ion Reporter TM and analysed using the filtering algorithm outlined above. A total of 16 somatic mutations were identified in the six AML patient samples tested. Centres 1 and 3 identified all 16 mutations, whereas Centre 2 identified 15/16, producing an analytical specificity for the gene panel of 97.9 % (95 % CI 89-99 %) [electronic supplementary Table 2 ]. A mean of 2.7 somatic mutations were detected in each AML patient sample (range 1-4), representing nine genes on the panel (ASXL1, DNMT3A, IDH1, IDH2, NPM1, NRAS, PTPN11, RUNX1, TET2), with ASXL1 and DNMT3A being the most frequent. NPM1 mutations were identified in one of the six QC samples, confirming results obtained at diagnosis by standard methodology at the referring centre. In addition, two frameshift deletions in ASXL1 not currently represented in COSMIC were identified in all centres and confirmed using IGV.
Allelic frequencies of the 16 mutations detected ranged from 5.6 to 53.3 % (median 44.4 %), with a high concordance between centres for mutations detected (Fig. 1) . Of note, Centre 2 did not report detection of the PTPN11 c.215C[A p.Ala72Asp mutation in sample three. Reanalysis of the data confirmed the presence of the missed mutation at a read depth of 302X, initially omitted as the read depth was \500X (in italics in electronic supplementary Table 2 and Fig. 1, mutation number 7) .
Reproducibility
Analysis of duplicate sample data showed both within and between run concordance, with the same number of variants detected at similar frequencies by all centres (electronic supplementary Table 2 ).
Discussion
There is considerable interest in translating targeted NGS of AML into clinical laboratories for routine detection of therapeutically actionable disease mutations [10, 11, 13, 14] . In this report, we have evaluated the inter-and intra-laboratory reproducibility and robustness of a commercial 19-gene AML panel in three separate clinical centres in the UK and Ireland. Performance of the panel was assessed using six AML patient samples run on the Ion PGM TM platform across all centres. A high level of concordance was observed, with 15/16 mutations detected. Centre 2 did not report a PTPN11 c.215C[A p.Ala72Asp mutation that was excluded as the number of reads generated for the sample was low (150,312) and the subsequent read depth at the target site did not achieve 500X. As a depth of coverage of 500X is necessary for confidence in calling low-level mutations (25 mutated reads are required for a 5 % burden), it is therefore essential to ensure appropriate coverage of all relevant amplicons to enable appropriate interrogation and interpretation of data produced. Improving efficiencies during the preanalytic stages could help achieve this and would reduce the variability in reads generated between samples and between centres. Optimisation of library equalisation or implementation of automated template preparation and chip loading (Ion Chef TM ) could increase reads generated and improve preanalytical consistency. Reduction of sample number per chip or repeat testing and combination of results for samples that prove difficult to sequence would help deliver sufficient read depth for further analysis.
Nevertheless, given the variation in reads generated per sample by each centre, the high concordance in the A limitation of this study was the limited number of genes available for analysis. Expansion of the panel to incorporate a greater number of relevant genes mutated in AML (e.g. splicing factors) would further improve its applicability.
Conclusions
The use of targeted panels in AML has the potential to overcome the limitations of standard Sanger sequencing in terms of time, the potential to sequence multiple gene targets at once, and the ability to quantify variant allelic frequencies. In a clinical diagnostic setting, these benefits translate into additional clinically relevant information and justify the application of limited resources to generate relevant information for clinical decision making. The implementation of common platforms and workflows to interrogate the mutational profile of AML patients will enable standardisation of results and further collaborative efforts between centres.
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